Literature DB >> 23372163

Preferential HLA-DRB1*11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells.

Nicoletta Sorvillo1, Simon D van Haren, Paul H Kaijen, Anja ten Brinke, Rob Fijnheer, Alexander B Meijer, Jan Voorberg.   

Abstract

Autoantibodies directed against ADAMTS13 prohibit the processing of von Willebrand factor multimers, initiating a rare and life-threatening disorder called acquired thrombotic thrombocytopenic purpura (TTP). Recently, HLA-DRB1*11 has been identified as a risk factor for the development of acquired TTP. Here, we identified ADAMTS13-derived peptides presented on MHC class II alleles from 17 healthy donors. Dendritic cells from a panel of both HLA-DRB1*11-positive and -negative donors were pulsed with ADAMTS13, and the HLA-DR-presented peptide repertoire was analyzed by mass spectrometry. Interestingly, at low antigen concentrations, HLA-DRB1*11- or DRB1*03-positive donors presented a limited number of CUB2-derived peptides. Pulsing of dendritic cells using higher concentrations of ADAMTS13 resulted in the presentation of larger numbers of ADAMTS13-derived peptides by both HLA-DRB1*11-positive and -negative donors. Although the presented peptides were derived from several ADAMTS13 domains, inspection of the peptide profiles revealed that CUB2 domain-derived peptides were presented with a higher efficiency when compared with other peptides. Remarkably, dendritic cells from DRB1*11 donors pulsed with higher concentrations of ADAMTS13-present derivatives of a single CUB2-derived peptide. We hypothesize that functional presentation of CUB2-derived peptides on HLA-DRB1*11 contributes to the onset of acquired TTP by stimulating low-affinity, self-reactive CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23372163     DOI: 10.1182/blood-2012-09-456780

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII.

Authors:  Nicoletta Sorvillo; Robin B Hartholt; Esther Bloem; Magdalena Sedek; Anja ten Brinke; Carmen van der Zwaan; Floris P van Alphen; Alexander B Meijer; Jan Voorberg
Journal:  Haematologica       Date:  2015-12-03       Impact factor: 9.941

Review 2.  Structure-function and regulation of ADAMTS-13 protease.

Authors:  X L Zheng
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

Review 3.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

Review 4.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2017-08-02       Impact factor: 22.113

5.  The class I scavenger receptor CD163 promotes internalization of ADAMTS13 by macrophages.

Authors:  Fabian C Verbij; Nicoletta Sorvillo; Paul H P Kaijen; Johana Hrdinova; Ivan Peyron; Rob Fijnheer; Anja Ten Brinke; Alexander B Meijer; Floris P J van Alphen; Timo K van den Berg; Jonas J H Graversen; Soren K Moestrup; Jan Voorberg
Journal:  Blood Adv       Date:  2017-01-16

Review 6.  Successful preventive treatment with cyclosporine in a patient with relapsed/refractory immune-mediated thrombotic thrombocytopenic purpura: a case report and review of the literature.

Authors:  Kaori Uchino; Kazuya Sakai; Saki Shinohara; Akifumi Matsuhisa; Yusuke Iida; Yuta Nakano; Saori Matsumura; Jo Kanasugi; Soichi Takasugi; Ayano Nakamura; Tomohiro Horio; Satsuki Murakami; Shohei Mizuno; Hidesuke Yamamoto; Ichiro Hanamura; Masanori Matsumoto; Akiyoshi Takami
Journal:  Int J Hematol       Date:  2022-03-10       Impact factor: 2.319

Review 7.  Disappearing acts of ADAMTS13.

Authors:  Jan Voorberg; Fabian C Verbij; Rob Fijnheer
Journal:  EBioMedicine       Date:  2015-07-10       Impact factor: 8.143

8.  The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope.

Authors:  Laurent Gilardin; Sandrine Delignat; Ivan Peyron; Mathieu Ing; Yu-Chun Lone; Bagirath Gangadharan; Baptiste Michard; Yousra Kherabi; Meenu Sharma; Anastas Pashov; Jean-Baptiste Latouche; Mohamad Hamieh; Olivier Toutirais; Pascale Loiseau; Lionel Galicier; Agnès Veyradier; Srini Kaveri; Bernard Maillère; Paul Coppo; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2017-07-27       Impact factor: 9.941

9.  Concentration and Subclass Distribution of Anti-ADAMTS13 IgG Autoantibodies in Different Stages of Acquired Idiopathic Thrombotic Thrombocytopenic Purpura.

Authors:  György Sinkovits; Ágnes Szilágyi; Péter Farkas; Dóra Inotai; Anikó Szilvási; Attila Tordai; Katalin Rázsó; Marienn Réti; Zoltán Prohászka
Journal:  Front Immunol       Date:  2018-07-16       Impact factor: 7.561

10.  Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors.

Authors:  Suella Martino; Mathieu Jamme; Christophe Deligny; Marc Busson; Pascale Loiseau; Elie Azoulay; Lionel Galicier; Frédéric Pène; François Provôt; Antoine Dossier; Samir Saheb; Agnès Veyradier; Paul Coppo
Journal:  PLoS One       Date:  2016-07-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.